Västra Hamnen: ViroGates - Steadily growing customer base

Västra Hamnen Corporate Finance has published a research update on ViroGates following its Quarterly Report for Q2 2020. The numbers were in line with our expectations, and we look positively on the newly added clinical routine customers, writes Västra Hamnen. 

• Increasing attention on efficient triaging due to COVID-19 pandemic
• Currently ten clinical routine customers
• We keep our valuation interval unchanged at DKK 68.00 – 100.50 per share

ViroGates’ report for Q2 2020 came in almost exactly in line with our forecasts.
Revenues, although markedly lower than a year ago, were precisely
as expected. The cost side came in a little lower than our forecasts, resulting
in a lower net loss compared with our estimates. The revenue drop was
related to a well-known problem at one customer hospital. Apart from
that, the underlying business development is progressing fairly well considering
the COVID-19 situation. If anything, the pandemic seems to increase
interest in the suPARnostic® products.

The full report is available here.

The research report is prepared as part of Market Focus, Västra Hamnen Corporate Finance's commissioned research offering.

This is a press release from Västra Hamnen Corporate Finance AB. 
Web: vhcorp.se
Twitter: @vhcorp_se

About Us

ViroGates is an international Medtech company headquartered in Denmark, north of Copenhagen, in the heart of Medicon Valley. ViroGates was founded in 2001, based on an invention coming from Hvidovre Hospital, Denmark. Inventor and co-founder Jesper Eugen-Olsen discovered the utility of the biomarker suPAR in HIV. More than 600 publications have followed, substantiating suPAR as one of the most promising biomarker tools for various areas of healthcare. ViroGates has developed a product line called suPARnostic® to make the suPAR test available as a commercially available test and the ambition is to get the test implemented and used for clinical decision making.